Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $362.6KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Parsons James T. | Director | Mar 11 '26 | Buy | $1.03 | 10,000 | $10,300 | 41,849 | Mar 13 08:00 AM |
| Kelly Jared | Chief Executive Officer | Mar 12 '26 | Buy | $0.96 | 5,050 | $4,848 | 114,050 | Mar 13 08:00 AM |
| Kelly Jared | Chief Executive Officer | Feb 12 '26 | Buy | $0.84 | 29,500 | $24,839 | 109,000 | Feb 13 07:00 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.